A multicenter analysis of adjuvant therapy after surgery for stage IIIC endometrial adenocarcinoma: A Korean Radiation Oncology Group study (KROG 13-17)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoon, Mee Sun | - |
dc.contributor.author | Park, Won | - |
dc.contributor.author | Huh, Seung Jae | - |
dc.contributor.author | Kim, Hak Jae | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Kim, Yong Bae | - |
dc.contributor.author | Kim, Joo-Young | - |
dc.contributor.author | Lee, Jong-Hoon | - |
dc.contributor.author | Kim, Hun Jung | - |
dc.contributor.author | Cha, Jihye | - |
dc.contributor.author | Kim, Jin Hee | - |
dc.contributor.author | Kim, Juree | - |
dc.contributor.author | Yoon, Won Sup | - |
dc.contributor.author | Choi, Jin Hwa | - |
dc.contributor.author | Chun, Mison | - |
dc.contributor.author | Choi, Youngmin | - |
dc.contributor.author | Chang, Sei Kyung | - |
dc.contributor.author | Lee, Kang Kyoo | - |
dc.contributor.author | Kim, Myungsoo | - |
dc.date.accessioned | 2021-09-04T13:13:39Z | - |
dc.date.available | 2021-09-04T13:13:39Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2015-09 | - |
dc.identifier.issn | 0090-8258 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/92671 | - |
dc.description.abstract | Objective. To investigate whether combined chemoradiotherapy (CTRT) confers a benefit for survival outcome over radiotherapy (RT) alone after primary surgery in patients with FIGO stage IIIC endometrial adenocarcinoma. Methods. We conducted a multicenter retrospective study of patients with surgical stage IIIC endometrial cancer from 1990 to 2011. Adjuvant RT alone was performed in 85 patients (403%) and adjuvant CTRT in 126 patients (59.7%). Disease-free survival (DFS) and overall survival (OS) were analyzed using Kaplan-Meier method and Cox proportional hazards model. Results. Stage 1110 and stage IIIC2 accounted for 63% and 37%, respectively. FIGO IIIC2 had a higher recurrence rate than FIGO IIIC1 (38.5% vs. 293%, p = 0.172). Five-year OS and DFS were lower in FIGO IIIC2 than FIGO IIIC1 (85.1% vs. 76.9%, p = 0.417; 71.0% vs. 59.2%, p = 0.108, respectively). Eighteen patients (13.5%) in stage IIIC1 developed PALN recurrence, whereas only one (3.3%) in stage IIIC2 had PALN recurrence (p = 0.001). In multivariate analysis, predictors of DFS were parametrial invasion (HR, 3.49; 95% CI, 1.83-6.64; p < 0.001), higher grade (HR, 2.78; 95% CI, 1.31-5.89; p = 0.008), and >3 positive pelvic nodes (HR, 1.84; 95% CI, 1.11-3.05; p = 0.019). Combined CTRT did not affect DFS or OS in IIIC1 and IIIC2 compared with RT alone. Conclusion. CTRT showed comparable survival outcome to RT alone. Half of relapses (46%) in stage IIIC1 occurred in PALN region, whereas relapse in stage IIIC2 primarily occurred in distant metastasis (90%). Future randomized studies are needed to determine which subgroup may be most likely to benefit from CCRT. (C) 2015 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE | - |
dc.subject | COMBINED CHEMOTHERAPY | - |
dc.subject | TREATMENT-OUTCOMES | - |
dc.subject | CANCER | - |
dc.subject | RADIOTHERAPY | - |
dc.subject | CARCINOMA | - |
dc.subject | TRIAL | - |
dc.subject | RISK | - |
dc.subject | SURVIVAL | - |
dc.title | A multicenter analysis of adjuvant therapy after surgery for stage IIIC endometrial adenocarcinoma: A Korean Radiation Oncology Group study (KROG 13-17) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Won Sup | - |
dc.identifier.doi | 10.1016/j.ygyno.2015.06.030 | - |
dc.identifier.scopusid | 2-s2.0-84941421415 | - |
dc.identifier.wosid | 000361269300006 | - |
dc.identifier.bibliographicCitation | GYNECOLOGIC ONCOLOGY, v.138, no.3, pp.519 - 525 | - |
dc.relation.isPartOf | GYNECOLOGIC ONCOLOGY | - |
dc.citation.title | GYNECOLOGIC ONCOLOGY | - |
dc.citation.volume | 138 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 519 | - |
dc.citation.endPage | 525 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Obstetrics & Gynecology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Obstetrics & Gynecology | - |
dc.subject.keywordPlus | COMBINED CHEMOTHERAPY | - |
dc.subject.keywordPlus | TREATMENT-OUTCOMES | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordAuthor | Endometrial cancer | - |
dc.subject.keywordAuthor | Adjuvant radiotherapy | - |
dc.subject.keywordAuthor | Adjuvant chemoradiotherapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.